New Delhi, August 11
The Centre has arrange an knowledgeable committee headed by NITI Aayog member VK Paul which is able to meet on Wednesday to think about the logistics and moral facets of procuring and administering the COVID-19 vaccine, the Union Health Ministry stated.
The committee on vaccine administration will have interaction with all stakeholders, together with state governments and vaccine producers, and its phrases of reference embrace deciding on appropriate vaccines, their procurement and supply and prioritising teams to manage them.
“It will also look into aspects related to logistics like cold chain and inventory, arrangement of resources for procuring the vaccine and issues of equity. This expert group will continue its engagement with all state governments and vaccine manufacturers in India,” stated Health Ministry Secretary Rajesh Bhushan at a press briefing on Tuesday.
He was responding to a query on whether or not India plans to tie up with Russia for procuring the vaccine which Moscow claims to have developed.
Asked if the federal government was taking a look at at-risk funding for vaccine producers and has estimated the variety of doses required not less than within the first six months, Bhushan stated these points have been participating the eye of the Health Ministry for “quite some time now”.
“We have consulted a large number of stakeholders and have also made certain projections, but it will be premature to share them with you as of now,” he added.
“The Expert Committee on Vaccine Administration under the chairmanship of Dr V K Paul, NITI Aayog will meet on August 12 to consider logistics & ethical aspects of procurement & administration of COVID-19 vaccine,” the Health Ministry tweeted.
Three vaccine candidates are in several levels of human scientific trials in India.
The phase-1 and a pair of human scientific trials of two of them, developed indigenously by Bharat Biotech, in collaboration with the Indian Council of Medical Research, and Zydus Cadila Ltd, are occurring, Bhushan stated.
The Serum Institute of India has been permitted for conducting Phase 2 and three human scientific trials of the third vaccine candidate developed by the Oxford University. The Pune-based institute has partnered with AstraZeneca for manufacturing it.
The section 1 trial of the Oxford vaccine candidate within the UK is full and section 2 trials are occurring within the UK and South Africa, whereas the phase-Three trial is underway in Brazil.
The Serum Institute has stated it has entered into a brand new partnership with worldwide vaccine alliance Gavi and Bill & Melinda Gates Foundation to speed up manufacturing and supply of as much as 100 million doses of vaccines for India and different low and middle-income international locations. — PTI